Xtandi in prostate cancer patients not treated with docetaxel – pro

Enzalutamide (Xtandi, MDV3100) is an androgen receptor antagonist drug reported to cause an up to an 89% decrease in PSA levels after a month of use. It is more potent than Casodex. Enzalutamide has approximately fivefold higher binding affinity for the androgen receptor (AR). It also does not promote translocation of AR to the nucleus and it prevents binding of AR to DNA and AR to coactivator proteins. In August of 2012, the U.S. Food and Drug Administration

Read more
Taxotere and Carboplatin for Prostate Cancer – pro

Chemotherapy is the recommended option once hormonal therapy or vaccine becomes ineffective. First line treatment of Taxotere and cabazitaxel hs recently been approvd for second line. Several studies have found activity for Taxotere and carboplatin combinations. The review by Oh et al concluded: "More recent Phase II studies of carboplatin suggested a moderate level of clinical and palliative activity when it was used as a single agent. However,

Read more